KZR-616 is a potent, peptide epoxyketone-based, and selective dual inhibitor of immunoproteasome subunit LMP7 (low molecular mass polypeptide-7)/LMP2 (multicatalytic endopeptidase complex subunit-1) with IC50 of 39 nM/139 nM . Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders. KZR-616 has anti-Inflammatory efficacy and is currently in clinical trials for treatment of rheumatic arthritis.

纯度：≥98%

CAS：1629677-75-3